Navigation Links
Penn researchers find new role for cancer protein p53
Date:3/2/2011

PHILADELPHIA - The gene for the protein p53 is the most frequently mutated in human cancer. It encodes a tumor suppressor, and traditionally researchers have assumed that it acts primarily as a regulator of how genes are made into proteins. Now, researchers at the University of Pennsylvania School of Medicine show that the protein has at least one other biochemical activity: controlling the metabolism of the sugar glucose, one of body's main sources of fuel. These new insights on a well-studied protein may be used to develop new cancer therapies.

Xiaolu Yang, PhD, associate professor of Cancer Biology at the Abramson Family Cancer Research Institute, along with Mian Wu, PhD, at the University of Science and Technology of China and Nanjing University, report in the current issue of Nature Cell Biology that p53 controls a molecular crossroads in the cell's glucose metabolic pathway.

They found that p53 physically binds to and inhibits an enzyme -- glucose-6-phosphate dehydrogenase (G6PD), which catalyzes the first step of the pathway. If p53 can't do its intended job, cells grow out of control.

Blocking this pathway shunts glucose away from energy storage and towards making genetic building blocks and lipids that contribute to cells' proliferation. p53 normally serves to dampen synthesis of molecules and cell reproduction by forcing the cell to take up less glucose.

In tumors, more than half of which carry mutations in the p53 gene, this routing function is abolished, enabling cells to build biomass and divide with abandon.

The findings provide a biochemical explanation for the Warburg effect, which explains how cancer cells, regardless of type, seem inevitably to boost their glucose consumption, but not in an energy efficient way.

"We found a connection between the most frequently mutated gene in cancer cells and how that mutation contributes to tumor growth," says Yang.

Making a Choice

When it takes up glucose, a cell has three choices: It can store the sugar, turn it into energy, or use it to make nucleic acids and lipids. As Yang explains, researchers have recognized for years that tumor cells consume glucose far faster than non-cancerous cells, but also that they don't seem to use the most energy efficient pathway to burn the fuel. What, then, were they doing with it?

Yang and his team found in both human colon cancer cells and fibroblast cells from mouse embryos that loss of p53 leads to increased glucose consumption though the energy inefficient pathway. This increase was associated with greater lipid synthesis and increased activity of G6PD, the enzyme that p53 is supposed to latch onto to shunt glucose into storage, not wild synthesis.

The team found that p53 binds directly to G6PD to inhibit its activity, apparently by interfering with the ability of G6PD to form a molecular complex. In contrast, p53 mutants lack this binding activity. In effect, demonstrating the binding role of p53 is distinct from its function as a regulator of protein transcription.

Intriguingly, Yang and his team estimate that the level of p53 is only about 3 percent that of G6PD. So in the cell, the p53/G6PD ratio is very low. But p53 has a dramatic effect on the overall activity of G6PD. This suggests that one p53 molecule can inactivate many G6PD molecules. This qualifies p53 as a catalyst. It appears to act almost as an enzyme to convert its much more abundant binding partner into an inactive form via transient rather than stable interactions.

Normally, when one protein binds to and inhibits another, that inhibition lasts only as long as the two proteins are bound together; dissolution of the complex almost invariably activates the released proteins. But in the case of p53 and G6PD, transient interaction with p53 is sufficient to convert G6PD into an inactive form - a property that is most often associated with enzymes. Says Yang, this enables p53, which at most is present at 10 percent the abundance of G6PD, to regulate its binding partner.

"By converting G6PD from active to inactive form, p53 also has an enzymatic function," says Yang. That kind of mechanism, he says, is "totally new" for p53, and a new paradigm for signal transduction in general.

"This non-stoichiometric effect of p53 on G6PDH is intriguing as it proposes a catalytic role for p53, something that even in the p53 world, which is accustomed to occasional twists, is surprising," wrote Eyal Gottlieb of Cancer Research UK in an accompanying editorial.

Now, says Yang, the question is whether this new role for p53 can be exploited to yield novel anticancer therapies. "Previously," he says, "people were hesitant to target the inefficient pathway because they thought it was stimulatory. Our data suggests the pathway is a good target."


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Related medicine news :

1. UCSF researchers uncover hormone pathway to fatty liver disease
2. Researchers pinpoint patients who receive greatest benefit from heart failure treatment
3. IDIBELL researchers discover a substance against the dark genome of cancer
4. Wayne State University researchers publish results settling multiple sclerosis debate
5. E-health must be a priority, researchers say
6. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
7. Mayo researchers, Rochester educators, students to present at science conference
8. Researchers work at the frontiers of islet cell transplantation
9. Brain Appears to Be a Task Machine, Researchers Say
10. Researchers develop outline that may help weigh benefits of new imaging technologies
11. University of Minnesota researchers study the use of computer vision to diagnose mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn researchers find new role for cancer protein p53
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: